# Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

> **NCT00121095** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cytogen Corporation** · enrollment: 69 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Samarium Sm-153 lexidronam + Docetaxel

## Key facts

- **NCT ID:** NCT00121095
- **Lead sponsor:** Cytogen Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2008-06
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2007-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121095, "Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00121095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*